WHO classification of Tumors of the Central Nervous System was revised in 2016 to incorporate the molecular status, such as isocitrate dehydrogenase (IDH) gene mutation and chromosomal 1p/19q codeletion, for diagnosing diffuse gliomas1. Here, IDH3A is linked to central nervous system cancer.